Evidence map›Paper›PMID 38274887›Full record

ArticleFrontiers in neurology2023

Elevation of inositol pyrophosphate IP

Masatoshi Ito, Natsuko Fujii, Saori Kohara, Masayuki Tanaka, Masaki Takao, Ban Mihara, Yuko Saito, Atsushi Mizuma, Taira Nakayama, Shizuka Netsu and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Using HILIC-MS/MS Method to Study Inositol Pyrophosphate.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Masatoshi ItoDepartment of Neurology, Tokai University School of Medicine, Isehara, Japan.
Natsuko FujiiDepartment of Neurology, Tokai University School of Medicine, Isehara, Japan.
Saori KoharaDepartment of Neurology, Tokai University School of Medicine, Isehara, Japan.
Masayuki TanakaSupport Center for Medical Research and Education, Tokai University, Isehara, Japan.
Masaki TakaoDepartment of Clinical Laboratory, National Center of Neurology and Psychiatry, National Center Hospital, Tokyo, Japan.
Ban MiharaDepartment of Neurology, Mihara Memorial Hospital, Isesaki, Japan.
Yuko SaitoDepartment of Neuropathology, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo, Japan.
Atsushi MizumaDepartment of Neurology, Tokai University School of Medicine, Isehara, Japan.
Taira NakayamaDepartment of Neurology, Tokai University School of Medicine, Isehara, Japan.
Shizuka NetsuDepartment of Neurology, Tokai University School of Medicine, Isehara, Japan.
Naoto SuzukiDepartment of Neurology, Tokai University School of Medicine, Isehara, Japan.
Akiyoshi KakitaDepartment of Pathology, Brain Research Institute, Niigata University, Niigata, Japan.
Eiichiro NagataDepartment of Neurology, Tokai University School of Medicine, Isehara, Japan.
Tokai University · JPInstitute of Brain and Blood Vessels · JPNational Center of Neurology and Psychiatry · JPNiigata University · JPTokyo Metropolitan Geriatric Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder associated with progressive impairment of spinal motor neurons. Continuous research endeavor is underway to fully understand the molecular mechanisms associating with this disorder. Although several studies have implied the involvement of inositol pyrophosphate IP Methods: We used a liquid chromatography-mass spectrometry (LC-MS) protocol originally-designed for mammalian IP Results: Conclusion: By directly analyzing IP

Indexed as

amyotrophic lateral sclerosisdiphosphoinositol pentakisphosphateinositol hexakisphosphateinositol pyrophosphateliquid chromatography-tandem mass spectrometry

Identifiers

PMID38274887
PMCPMC10808411
OpenAlexW4390745916

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.